ImmunityBio(IBRX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Full year net product revenue for ANKTIVA was $113 million, representing a 700% year-over-year increase from $14.1 million in 2024 [35] - The company achieved a 750% increase in unit sales volume over the same period, indicating revenue growth driven by clinical adoption rather than pricing [35][36] - The fourth quarter net product revenue increased from $31.1 million to $38.3 million, reflecting a 20% quarter-over-quarter growth from Q3 to Q4 [44] Business Line Data and Key Metrics Changes - ANKTIVA is now authorized across 33 countries, including major jurisdictions like the United States, the United Kingdom, Saudi Arabia, and the European Union, marking rapid international expansion [37] - The U.S. remains the largest and most mature commercial market, with strong uptake among urologists and oncologists treating BCG-unresponsive non-muscle invasive bladder cancer [38][40] Market Data and Key Metrics Changes - The European Commission granted conditional marketing authorization for ANKTIVA in February 2026, covering all 27 EU member states plus Iceland, Norway, and Liechtenstein [41] - In Saudi Arabia, ANKTIVA received approvals for both bladder cancer and metastatic non-small cell lung cancer, marking the first worldwide authorization for lung cancer [42] Company Strategy and Development Direction - The company aims to grow from a commercial stage immunotherapy business into a diversified oncology platform, leveraging three platform technologies: ANKTIVA, CAR-NK cell therapy, and DNA vaccine vector technology [47][48] - The strategy includes pursuing label expansions for BCG-naïve bladder cancer and international expansion for non-small cell lung cancer [48] Management's Comments on Operating Environment and Future Outlook - Management highlighted the favorable tolerability profile and durable response of ANKTIVA, which has led to repeat prescribing behavior among physicians [39] - The company is preparing for commercial launches in Saudi Arabia and Europe, indicating confidence in sustained growth as awareness of ANKTIVA increases [40][41] Other Important Information - The company reported a full year net loss attributable to common stockholders of $351.4 million, a reduction from $413.6 million in 2024, reflecting progress in converting revenue growth into a narrowing loss profile [46] - The company has established an artificial intelligence solution called Ask IB to drive AI-powered advancements across all areas of the business [52] Q&A Session Summary Question: What is the commercial strategy for ANKTIVA in the U.S.? - The company is focused on building strong relationships with key opinion leaders and expanding its reach into community practices where most bladder cancer patients are treated [39] Question: How does the company plan to address the European market? - The company has partnered with Accord Healthcare to deploy over 100 dedicated professionals across 31 countries in the EU, ensuring rapid commercial launch [41] Question: What are the future plans for clinical trials? - The company plans to submit a BLA for the BCG-naïve indication in Q4 2026, which would significantly broaden the addressable market for bladder cancer [51]